Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$100,000.00
Targeting Reactive Microgliosis in Alzheimer's Disease: Developing a Nano-Delivery System for Celastrol
EF 2009-10
Résumé
Nanomedicine is a newly emerging discipline that focuses on the use of nano-sized technological products for their use in medical diagnosis and treatment. New developments in this field point to the use of safe, synthetic nano-sized gels to impede the formation of harmful protein deposits, thus having considerable applications in Alzheimer's disease (AD), the hallmark of which is characterized by similar deposits that block neural activity in the brains of those affected. In the sporadic form of this progressive neurodegenerative disease, for which age is the most common risk factor, both the increased production of these noxious deposits and the impairment of their clearance are accredited for the increased accumulation observed with aging. The present study proposes to exploit the potential synergistic action between these novel nano-gel assemblies which inhibit deposit formation and drugs capable of stimulating brain mechanisms that typically promote their clearance. The overall objective is to develop a feasible approach that takes advantage of this synergistic action effectively and efficiently, intervening in disease progression as early as clinically possible. This is a conceptually unique strategy in that it not only directly targets the visible markers believed to significantly contribute to the pathogenesis of AD, but it simultaneously enhances the integrity of the brains protective mechanisms, preventing further damage. Research findings from this study will aid in the development of an appropriate therapeutic strategy for this debilitating neurodegenerative disorder, for which the present burden on the Canadian medical system totals more than $3 billion (Health Canada). More generally, this study will demonstrate the applicability of nano-technological approaches to the treatment of mental illnesses.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
197141
Name
Boridy Sebastien M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Targeting Reactive Microgliosis in Alzheimer's Disease: Developing a Nano-Delivery System for Celastrol
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Chaperone Defense System; Drug Delivery; Microgliosis; Nanomedicine; Neuroprotection
Abstract
Nanomedicine is a newly emerging discipline that focuses on the use of nano-sized technological products for their use in medical diagnosis and treatment. New developments in this field point to the use of safe, synthetic nano-sized gels to impede the formation of harmful protein deposits, thus having considerable applications in Alzheimer's disease (AD), the hallmark of which is characterized by similar deposits that block neural activity in the brains of those affected. In the sporadic form of this progressive neurodegenerative disease, for which age is the most common risk factor, both the increased production of these noxious deposits and the impairment of their clearance are accredited for the increased accumulation observed with aging. The present study proposes to exploit the potential synergistic action between these novel nano-gel assemblies which inhibit deposit formation and drugs capable of stimulating brain mechanisms that typically promote their clearance. The overall objective is to develop a feasible approach that takes advantage of this synergistic action effectively and efficiently, intervening in disease progression as early as clinically possible. This is a conceptually unique strategy in that it not only directly targets the visible markers believed to significantly contribute to the pathogenesis of AD, but it simultaneously enhances the integrity of the brains protective mechanisms, preventing further damage. Research findings from this study will aid in the development of an appropriate therapeutic strategy for this debilitating neurodegenerative disorder, for which the present burden on the Canadian medical system totals more than $3 billion (Health Canada). More generally, this study will demonstrate the applicability of nano-technological approaches to the treatment of mental illnesses.
Competitiondate
200911
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Boridy, Sebastien M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~